Cipla appoints Peter Lankau as independent director on its board

Cipla Ltd, a global pharmaceutical giant on Monday announced the appointment of Peter Lankau as an independent director on its board with effect from January 10.

Lankau has a Bachelors of Science degree in Biology from the State University of New York at Albany, USA. He has over 30 years of management experience in developing and commercialising pharmaceutical products.

"Lankau brings with him a deep understanding of the US Pharmaceutical market that will help us steer the future thinking of our Company for this focus market." Cipla's Non-Executive Chairman Y K Hamied said in a statement here.

He is currently a principal of Lankau Consulting LLC. He was previously Executive Chairman of the Board for Nautilus Neurosciences, Inc., Chairman & CEO of Logical Therapeutics, Inc and President & CEO of Endo Pharmaceuticals Inc. Prior to Endo Pharmaceuticals Inc, he was VP, Sales and Marketing for Alpharma, Inc. He began his pharmaceutical career with Rhone-Poulenc Rorer, Inc which is now known as Sanofi.

Lankau currently serves on the Board of Directors of ANI Pharmaceuticals, Inc. and Phosphagenics Limited and also on the Board of Advisors of Orchard Venture Partners, a life sciences venture capital firm.